Legend Biotech (LEGN) Debt to Equity (2021 - 2025)
Historic Debt to Equity for Legend Biotech (LEGN) over the last 5 years, with Q3 2025 value amounting to $0.14.
- Legend Biotech's Debt to Equity fell 4683.96% to $0.14 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.14, marking a year-over-year decrease of 4683.96%. This contributed to the annual value of $0.22 for FY2023, which is 3587.1% down from last year.
- Legend Biotech's Debt to Equity amounted to $0.14 in Q3 2025, which was down 4683.96% from $0.3 recorded in Q2 2025.
- In the past 5 years, Legend Biotech's Debt to Equity ranged from a high of $0.41 in Q1 2023 and a low of $0.05 during Q2 2021
- Moreover, its 5-year median value for Debt to Equity was $0.25 (2024), whereas its average is $0.24.
- Per our database at Business Quant, Legend Biotech's Debt to Equity skyrocketed by 13808.35% in 2023 and then tumbled by 4683.96% in 2025.
- Legend Biotech's Debt to Equity (Quarter) stood at $0.16 in 2021, then surged by 122.9% to $0.35 in 2022, then crashed by 35.87% to $0.22 in 2023, then increased by 18.21% to $0.27 in 2024, then tumbled by 46.84% to $0.14 in 2025.
- Its last three reported values are $0.14 in Q3 2025, $0.3 for Q2 2025, and $0.3 during Q1 2025.